Cambridge Research Biochemicals News and Blog

Latest news

1 Aug 2013

Cambridge Research Biochemicals confirms supplier status with contract renewal

Cambridge Research Biochemicals, the specialist peptide and custom antibody manufacturer based in the North East of England, has demonstrated customer satisfaction with the extension of an important contract in the medical research field.

CRB, a leading peptide manufacturer and custom antibody supplier which is based in Billingham on Teesside, has announced that it has renewed its contract with UK SBS, formerly known as RCUK Shared Services Centre Ltd (RCUK SSC Ltd). The original contract dates back to 2010.

The contract means that the company will continue to supply UK SBS with custom-synthesised peptides and custom-generated polyclonal and monoclonal antibodies for a further 12 months with an additional year’s extension.

The contract is significant because it means that CRB can build on its existing relationship with the Medical Research Council and other UK Research Institutes as well as exploring opportunities to work with a wider pool of Universities.

CRB Commercial Director Emily Humphrys said: “This is a significant announcement for us because it demonstrates the progress we have made as a company over the past three years. This is a demanding field and the renewal of the contract recognises our commitment to the very highest standards.”

“Our products play an important part in early research into all known human diseases; our tools are extremely versatile and useful and this renewal of contract means that we can continue to expand our offering.”

“CRB is noted for providing high quality research peptide and antibody tools and we are recognised for constantly reaching the high technical and service standards required by the Research Councils.”

Mike Reilly, Category Manager for UK SBS Ltd, said: “The renewal of this contract illustrates the faith that we have in the excellent work being done by the team at CRB.

“During the time that we have worked together, they have constantly operated under a high level of professionalism and exhibited an impressive commitment to the quality and ethical standards of the products that they supply to us. We look forward to developing our relationship in the years to come.”

CRB says that the renewal further strengthens its position as a key supplier of custom-synthesised peptides and custom-generated polyclonal and monoclonal antibodies.

Over recent years, CRB has advanced its own research and collaboration projects, increasing the company’s innovation and technical prowess. This included being named in 2009 as one of the partners in the BIOSCENT project, part of the European Seventh Framework Programme for research and technological development (FP7), providing peptide synthesis expertise and synthetic peptides to support research in peptide scaffolds as heart patches; supporting a CASE studentship at Durham University to work on chemical ligation of long peptides (2011) and appointment to the Royal Society of Chemistry (RSC) Protein and Peptide Science Interest group for the advancement of peptide chemistry and protein science (2012) .